In addition to the exploratory preclinicals on other

New Post Public Reply Private Reply Replies (0) Message Board
Ramjet
731
In addition to the exploratory preclinicals on other oncology indications (TNBC), papers, and mouse studies, we also have Two trials with people, mssCRC and Alzheimer's Plus an inflammation trial that will get under way soon (or maybe it has already).

Someone remind me of when the inflammation trial will commence or when it already commenced, and when it is likely to show results. The point is, in just a year or so, Dr J and team have done an outstanding job of moving this company forward. My bet is on them.

All of these trials involving people will provide data, and this will enable the share price to move higher and blow the short sellers away. Those who are smart will buy-to-cover soon. Those who don't will pay the price eventually.

In the meantime, as a shareholder of 4 years (adding all the time, as money permits) I'm going to sit back, relax, and wait for the data to provide a licensing opportunity or partnership, or opportunity (in the case of Alzheimers) to provide funding alone.

Dr J said they have the funding they need for now, and so long as I don't sell now, then I can partake of the rewards when the data comes in. Staying Long, Adding, and Ignoring the background noise.

I won't make the same mistake I made with Apple. And I'm not looking for an Apple here, just a company that will truly help people and reward us handsomely in the meantime

Go LL
Ramjet

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Astrana Health Strengthens Market Position with Recent Acquisitions

Updated Category News Views 604

Astrana Health Completes Strategic Acquisitions Astrana Health, Inc. (NASDAQ:ASTH), a prominent management consulting services provider, has successfully concluded its acquisition of several healthcare entities. This strategic move represents a significant milestone in the expansion of its operations within the healthcare management sector. The company recently finalized...

Continue Reading
Celebrating 65 Years: A Journey Through Innovations in Flexography

Updated Category News Views 88

Anderson & Vreeland: A Milestone Celebration Anderson & Vreeland Inc. (NASDAQ: A&V), known affectionately as A&V, proudly celebrates its 65th anniversary, reflecting on over six decades of pioneering service in the flexographic printing industry. Since launching operations in January 1961, the company has continually adapted and evolved to serve the needs of its customers...

Continue Reading
Hyatt on the Hook: $15.5M Verdict Spurs Industry Wake-Up Call

Updated Category News Views 21

Hyatt Takes a Hit: $15.5 Million Verdict The courtroom doors swung open, and out came a staggering $15.5 million verdict against Hyatt, plastering the corporation's name across every investor's radar today. Not some chump change, I tell ya. This hefty figure stems from a case involving the tragic death of Cindy Gonzalez, a diabetic hotel guest left high and dry by...

Continue Reading
Rocket Lab USA Inc Faces Legal Challenges Amid Performance Issues

Updated Category News Views 518

Legal Concerns Surrounding Rocket Lab USA Inc. Recent events have raised significant legal concerns for Rocket Lab USA, Inc. (NASDAQ: RKLB). The national shareholder rights law firm Bragar Eagel & Squire, P.C. is actively investigating potential claims against the company on behalf of its long-term stockholders. These inquiries stem from a class action lawsuit filed...

Continue Reading
Klarna Group PLC: Short Interest and Market Sentiment Insights

Updated Category News Views 277

Analyzing Market Sentiment Around Klarna Group PLC A storm’s brewing if you’re watching Klarna Group PLC's short interest data. Just to give you a pulse on the situation, short interest has spiked by 21.74% since the last report. We’re talking about a whopping 16.95 million shares sold short, which translates to 6.16% of available shares. Now, as the dust settles,...

Continue Reading